Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

— Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation. Combination dose expansion is under way. — Among the 28 evaluable patients who received the combination regimen, while 85.7% of the patients […]

Indian bank teller finds cash cow in Taiwanese guavas

In November 2019, then Indian bank teller Kapil Sharma did not know he was going to share a bond with Taiwan because of its guavas.Laid off from his job, Sharma found it difficult to find employment following the rapid spread of COVID-19 and so returne…